Phase 1b Study of CB-280 for CF Chronic Lung Infections May Open by September

Phase 1b Study of CB-280 for CF Chronic Lung Infections May Open by September
5
(2)

Calithera Biosciences announced plans to open by September a first clinical study of its oral investigational therapy CB-280 in people with cystic fibrosis (CF).

The Phase 1b, dose-escalating trial (NCT04279769) in up to 32 adults with cystic fibrosis and chronic lung infections caused by Pseudomonas aeruginosa was expected to begin enrolling in April, but its launch was pushed back due to the COVID-19 pandemic.

It follows a now completed Phase 1 trial in healthy volunteers that assessed the safety, tolerability, and pharmacological properties of this small molecule treatment for airway disease in CF, the company announced in a press release.

CB-280 is a selective oral inhibitor of the enzyme arginase, which is responsible for converting the amino acid arginine into urea and ornithine. In CF patients, this enzyme is overly active, leading to a shortage of arginine in the lungs, which in turn reduces anti-microbial airway resistance and lung function.

By blocking arginase and increasing the levels of arginine in lungs, CB-280 is expected to improve patients’ lung function and resistance to microbes that cause lung infections, including the bacteria P. aeruginosa.

Patients enrolled in the Phase 1b trial will be randomly assigned to one of four capsule doses of CB-280 (50, 100, 200, or 400 mg), or to a matched placebo, given orally twice-a-day for 14 days.

The study’s main goal is to assess the safety and tolerability of CB-280, based on the incidence and severity of observed adverse events.

Additional study goals include assessing the medication’s pharmacokinetic properties, such as the maximum concentration of CB-280 measure in treated patients’ plasma. (Pharmacokinetics is the study of how a therapy is absorbed, distributed, metabolized in the body, and eliminated. Plasma is the liquid portion of blood that remains after all blood cells are removed.)

Additional patient groups to test intermediate doses of the medication may still be added to the trial’s protocol, depending on safety data obtained in planned dose groups.

Calithera is also planning to launch a Phase 2 trial (NCT04265534) assessing telaglenastat (CB-839), its anti-cancer treatment candidate, in the third quarter of 2020. The trial will evaluate telaglenastat in combination with standard of care in patients with advanced non-small cell lung cancer (NSCLC).

“We continued our positive momentum from 2019 into the first quarter of 2020 … advancing our key clinical development programs,” Susan Molineaux, PhD, president and CEO of Calithera, said in the release.

Joana holds a BSc in Biology, a MSc in Evolutionary and Developmental Biology and a PhD in Biomedical Sciences from Universidade de Lisboa, Portugal. Her work has been focused on the impact of non-canonical Wnt signaling in the collective behavior of endothelial cells — cells that made up the lining of blood vessels — found in the umbilical cord of newborns.
Total Posts: 336

Patrícia holds her PhD in Medical Microbiology and Infectious Diseases from the Leiden University Medical Center in Leiden, The Netherlands. She has studied Applied Biology at Universidade do Minho and was a postdoctoral research fellow at Instituto de Medicina Molecular in Lisbon, Portugal. Her work has been focused on molecular genetic traits of infectious agents such as viruses and parasites.

×
Joana holds a BSc in Biology, a MSc in Evolutionary and Developmental Biology and a PhD in Biomedical Sciences from Universidade de Lisboa, Portugal. Her work has been focused on the impact of non-canonical Wnt signaling in the collective behavior of endothelial cells — cells that made up the lining of blood vessels — found in the umbilical cord of newborns.
Latest Posts
  • Medicine by Design awards
  • Konglomerate Games
  • Gastrointestinal problems and CF
  • Trikafta and Canada forecast

How useful was this post?

Click on a star to rate it!

Average rating 5 / 5. Vote count: 2

No votes so far! Be the first to rate this post.

As you found this post useful...

Follow us on social media!

We are sorry that this post was not useful for you!

Let us improve this post!

Tell us how we can improve this post?

Leave a Comment

Your email address will not be published. Required fields are marked *